Although patients with lung adenocarcinoma that harbors EGFR mutations benefit from EGFR-TKI therapy, Kras mutations appear to confer intrinsic resistance to EGFR-TKIs [34–36]. This evidence concerns the gene KRAS and lung adenocarcinoma.